Halozyme Therapeutics, Inc. — FY2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. The filing also reports unaudited fourth-quarter results. Halozyme develops enzyme-based therapies, with its Enhanze technology licensed to biopharmaceutical partners and PEGPH20 as its lead proprietary oncology candidate. It reported net losses and an accumulated deficit of $450.4 million.
Financial performance and position
| Metric | FY2014 | FY2013 | Change / context |
|---|---|---|---|
| Total revenue | $75.3 million | $54.8 million | Up 37%; growth included a $15.0 million Janssen license fee and higher product sales and royalties |
| Product sales, net | $37.8 million | $24.4 million | Up 55%; included $23.5 million in bulk rHuPH20 sales to Roche and $13.2 million in Hylenex sales |
| Royalties | $9.4 million | $0.03 million | Primarily from Roche’s Herceptin SC sales |
| Net loss | $68.4 million | $83.5 million | Loss narrowed; loss per share was $0.56 versus $0.74 |
| Operating loss | $63.0 million | $80.4 million | Research and development expense fell to $79.7 million from $96.6 million |
| Operating cash flow | $(47.5) million | $(49.3) million | Cash used in operations remained substantial |
| Cash, cash equivalents and marketable securities | $135.6 million | $71.5 million | At December 31; includes $61.4 million cash and $74.2 million marketable securities |
| Debt | $50.0 million gross; $49.9 million net | $50.0 million gross | 7.55% interest rate; maturity January 2018 |
| Working capital | $137.0 million | $70.3 million | Current assets were $161.3 million; current liabilities were $24.3 million |
Product-sales gross profit was approximately $15.1 million, or 40% of product sales, versus approximately $18.2 million, or 74%, in 2013. Comparability is affected by manufacturing costs for collaboration products being expensed as R&D before approval and capitalized as inventory after approval; 2013 gross profit also benefited from previously expensed manufacturing costs.
Fourth-quarter 2014 revenue was $30.4 million and net loss was $5.3 million, compared with revenue of $12.5 million and net loss of $22.0 million in fourth-quarter 2013. The 2014 quarter included the $15.0 million Janssen license fee.
Material changes and business developments
- Halozyme raised $107.7 million net in a February 2014 common-stock offering; year-end shares outstanding increased to 125.7 million from 114.5 million a year earlier.
- Roche’s European launches of Herceptin SC and MabThera SC, and Baxter’s U.S. launch of HYQVIA after FDA approval, expanded commercial use of Enhanze. HYQVIA was Halozyme’s first U.S.-approved BLA product using rHuPH20.
- Roche accounted for 57% of FY2014 revenue and Janssen 20%, demonstrating substantial customer and collaboration concentration.
- Halozyme received a $15.0 million upfront fee under its new Janssen collaboration. The company reported eligibility for up to $566 million in additional development, regulatory and sales-based payments, which are contingent and not assured.
- Management refocused investment on PEGPH20 and Enhanze and reduced the workforce by approximately 13%; restructuring expense was $1.2 million.
Outlook, risks and unusual items
- Management estimated 2015 net cash burn of approximately $35–$45 million and said available cash and securities were expected to fund operations for at least 12 months. R&D expense was expected to rise as clinical programs and manufacturing development progressed.
- PEGPH20 was in Phase 2 testing for metastatic pancreatic cancer and Phase 1b/2 testing in non-small cell lung cancer. FDA Fast Track and U.S. and European orphan designations were granted for pancreatic cancer; these designations do not constitute approval.
- Study 109-202 was placed on clinical hold in April 2014 over a possible thromboembolic-event imbalance, then resumed under a revised protocol with risk exclusions, anticoagulant prophylaxis and additional safety monitoring. Interim Stage 1 results showed a 5.5-month versus 4.8-month progression-free survival result overall; the high-HA subgroup showed 9.2 versus 4.3 months. These were interim findings, and the trial remained subject to safety monitoring and further results.
- Management reported 2014 R&D spending of $34.9 million on PEGPH20. Diabetes development was deprioritized: the company planned no substantial additional spending on the insulin-pump program beyond trial closeout, pending FDA clarity and potential partners.
- Cash generation depends on partner development, regulatory approvals, product launches, royalties and contingent milestones. The company had recurring losses, negative operating cash flow, dependence on a small number of collaborators and outsourced manufacturers, and no assurance of profitability.
- Debt is secured by substantially all company and subsidiary assets other than specified exclusions, carries restrictive covenants, and includes a final payment of $4.25 million. A January 2015 amendment provided interest-only payments through January 2016, followed by principal and interest through the January 2018 maturity.
- The filing disclosed no material legal proceedings. Management and the auditor reported effective internal control over financial reporting; the financial statements received an unqualified audit opinion.
Most important facts for investors to verify
- Updated PEGPH20 efficacy and safety results, especially thromboembolic-event rates and whether the revised protocol controls that risk.
- Whether the high-HA patient subgroup findings are confirmed in adequately powered studies and support a viable registration path and companion diagnostic.
- Actual 2015 cash burn, liquidity runway, and any need for additional financing or dilution.
- Commercial uptake, royalties and supply economics for Roche’s and Baxter’s products, alongside revenue concentration and collaborator performance.
- Manufacturing capacity, qualification and cost reductions from the planned transition of Hylenex fill-and-finish to Patheon and scale-up of PEGPH20.
- Progress of the Janssen collaboration and achievement of any contingent milestones; the stated potential payments are not guaranteed.